{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-296143","form_type":"8-K","ticker":"NERV","cik":"0001598646","company_name":"Minerva Neurosciences, Inc.","filed_at":"2021-10-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.217363+00:00","generated_at":"2026-06-28T21:28:42.939067+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Minerva Neurosciences promotes Geoff Race to President, Frederick Ahlholm to CFO; pre-NDA meeting planned","bullets":["Geoff Race promoted to President effective Oct 11, 2021; he was EVP, CFO, and CBO.","Frederick Ahlholm promoted to CFO effective Oct 11, 2021; previously SVP and CAO.","Company plans to submit pre-NDA meeting request to FDA for roluperidone; potential NDA in H1 2022.","Ahlholm's base salary increased from $373,890 to $400,000; Race's base salary remains at $442,293."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-296143","json":"https://secwatch.observer/filing/0001193125-21-296143.json","markdown":"https://secwatch.observer/filing/0001193125-21-296143.md","text":"https://secwatch.observer/filing/0001193125-21-296143.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1598646/000119312521296143/0001193125-21-296143-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1598646/000119312521296143/d236669d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T21:28:42.939067+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d096f9c14","claim":"Geoffrey Race was appointed as President at Minerva Neurosciences, Inc..","evidence_excerpt":"On October 11, 2021, Minerva Neurosciences, Inc. (the “Company”) announced the appointment of Geoffrey Race as the Company’s President, effective October 11, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1598646/000119312521296143/0001193125-21-296143-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"bbed1b5f62","claim":"Frederick Ahlholm was appointed as Chief Financial Officer at Minerva Neurosciences, Inc..","evidence_excerpt":"On October 11, 2021, the Company announced the appointment of Frederick Ahlholm as the Company’s Chief Financial Officer (principal financial officer and principal accounting officer), effective October 11, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1598646/000119312521296143/0001193125-21-296143-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}